US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Roche Holding Ltd

44.91

+0.24000.54%

Post-market: 44.910.00000.00%16:13 EDT

Volume:1.51M

Turnover:67.84M

Market Cap:286.12B

PE:28.96

High:45.21

Open:44.55

Low:44.50

Close:44.67

52wk High:45.94

52wk Low:34.10

Shares:6.37B

Float Shares:6.37B

Volume Ratio:1.11

T/O Rate:0.02%

Dividend:1.53

Dividend Rate:3.40%

EPS(TTM):1.55

EPS(LYR):2.14

ROE:31.32%

ROA:13.30%

PB:7.92

PE(LYR):21.02

Loading ...

Overview Company News Filings

Roche Says Breast-Cancer Drug Beats Standard Treatment in Late-Stage Trial

Roche reports Phase 3 data for satralizumab in SatraGO-1, SatraGO-2

Underwhelming Roche data helps Veridian’s position in TED, says Jefferies

Berenberg Bank Reaffirms Their Hold Rating on Roche Holding (RHHBY)

Roche Sets Gene-Sequencing Record. It's a Challenge for Illumina. -- Barrons.com

Roche announces Direct-to-Patient program for Xofluza

Roche Holding AG Flat Monday

Roche Gets FDA Approval For Alzheimer's Disease Test

Roche to present 30 abstracts at ESMO, evERA study met co-primary endpoints

AstraZeneca's Enhertu Could Become Top Early Breast Cancer Therapy -- Market Talk

Roche Holding AG Rises Wednesday

Roche's Genentech Gets FDA Approval for Lung Cancer Treatment

FDA approves Genentech’s Tecentriq + Lurbinectedin in ES-SCLC

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

U.S. Tariffs Pose Limited Risk to Big Swiss Pharma Groups -- Market Talk

European Pharmaceutical Stocks Fall On New Trump Tariffs -- Market Talk

Trump to Slap New Tariffs on Pharma, Big Trucks -- 2nd Update

Genentech presents new Ocrevus, fenebrutinib data at ECTRIMS congress

Oppenheimer reiterates Buy on Olema, sees evERA readthrough to persevERA

Roche to Launch Late-Stage Trial of Experimental Obesity Drug in 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RHHBY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RHHBY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","market":"US","secType":"STK","nameCN":"Roche Holding Ltd","latestPrice":44.91,"timestamp":1760731200000,"preClose":44.67,"halted":0,"volume":1508399,"hourTrading":{"tag":"盘后","latestPrice":44.91,"preClose":44.91,"latestTime":"16:13 EDT","volume":2124,"amount":95577.23999999999,"timestamp":1760732012878},"delay":15,"floatShares":6371000000,"shares":6371000000,"eps":1.550894,"marketStatus":"Market Closed","change":0.24,"latestTime":"10-17 16:00:00 EDT Delay","open":44.55,"high":45.21,"low":44.5,"amount":67842077.70110008,"amplitude":0.015894,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":1.550894,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1760947200000},"marketStatusCode":7,"adr":0,"adrRate":0.125,"exchange":"OTCQX","adjPreClose":44.67,"volumeRatio":1.1074856506858959},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","floatShares":6371000000,"roa":"13.30%","roe":"31.32%","lyrEps":2.136203,"volumeRatio":1.1074856506858959,"shares":6371000000,"dividePrice":1.528373,"high":45.21,"amplitude":0.015894,"preClose":44.67,"low":44.5,"week52Low":34.103,"pbRate":"7.92","psRate":"3.58","week52High":45.94,"institutionHeld":0.0396,"latestPrice":44.91,"eps":1.550894,"divideRate":0.034032,"volume":1508399,"delay":15,"ttmEps":1.550894,"open":44.55,"prevYearClose":34.88,"prevWeekClose":45.66,"prevMonthClose":41.81,"prevQuarterClose":41.81,"fiveDayClose":45.66,"twentyDayClose":41.79,"sixtyDayClose":41.44},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RHHBY\",params:#limit:5,,,undefined,":[{"date":"2025-03-28","symbol":"RHHBY","amount":0.855932,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-28","defaultRemindTime":1743168600000,"name":"罗氏控股","lastCurrency":null,"lastExecuteDate":null,"recordDate":null,"payableDate":"2025-03-28","currency":"USD","dateTimestamp":1743134400000,"payDate":null},{"date":"2024-07-25","symbol":"RHHBY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1721894400000,"name":null,"time":"","dateTimestamp":1721880000000,"actualEps":null},{"date":"2024-03-14","symbol":"RHHBY","amount":0.8751559,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-15","defaultRemindTime":1710423000000,"name":"罗氏控股","recordDate":null,"payableDate":"2024-03-15","currency":"USD","dateTimestamp":1710388800000,"payDate":null},{"market":"US","date":"2024-02-01","symbol":"RHHBY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1706763600000,"reportTimeType":"","actualEps":null},{"date":"2023-07-27","symbol":"RHHBY","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690444800000,"name":null,"time":"Pre-Market","dateTimestamp":1690430400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RHHBY\",market:\"US\",,,undefined,":[{"executeDate":"2016-03-02","recordDate":"2016-03-04","paymentDate":"2016-04-22","value":0.837655,"currency":"USD"},{"executeDate":"2019-03-07","recordDate":"2019-03-08","paymentDate":"2019-03-18","value":0.691071,"currency":"USD"},{"executeDate":"2020-03-19","recordDate":"2020-03-20","paymentDate":"2020-03-30","value":0.7280819,"currency":"USD"},{"executeDate":"2021-03-18","recordDate":"2021-03-19","paymentDate":"2021-03-29","value":0.8108518,"currency":"USD"},{"executeDate":"2022-03-17","recordDate":"2022-03-18","paymentDate":"2022-03-28","value":1.2649619,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RHHBY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.375,"hold":0.375,"sell":0.125,"strongSell":0,"meanLabel":"BUY","meanPercent":0.375,"analysts":8,"updateTime":1759636800000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RHHBY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2576622092","title":"Roche Says Breast-Cancer Drug Beats Standard Treatment in Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2576622092","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576622092?lang=en_us&edition=fundamental","pubTime":"2025-10-18 13:00","pubTimestamp":1760763600,"startTime":"0","endTime":"0","summary":"Roche Holding said experimental drug giredestrant outperformed the standard-of-care treatment in a late-stage trial, showing significant improvements for breast-cancer patients.The Swiss pharma group said Saturday that the giredestrant regimen cut the risk of disease progression or death by 44% compared with standard-of-care treatment. Patients whose tumors carried estrogen receptor 1 mutations--a form resistant to standard hormone drugs--saw a 62% reduction in the risk of disease progression or death compared with standard therapy.Roche said tolerability was another encouraging finding, with a mid-single-digit discontinuation rate, below that in the standard-of-care treatment regimen. Trial results also showed that giredestrant didn't lead to side effects typical of standard-of-care therapy, notably ocular toxicity that commonly affects patients undergoing standard-of-care treatment.The company presented detailed results of the study at the annual congress of the European Society for ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMP","RHHBY","SSI","03165","BK4007","BK4124"],"gpt_icon":0},{"id":"2576065889","title":"Roche reports Phase 3 data for satralizumab in SatraGO-1, SatraGO-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2576065889","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576065889?lang=en_us&edition=fundamental","pubTime":"2025-10-18 02:10","pubTimestamp":1760724615,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) presented at ASPORS meeting primary results of the Phase 3 SatraGO-1 and SatraGO-2 trials — Efficacy and Safety of Satralizumab in Th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-reports-phase-3-data-for-satralizumab-in-satrago-1-satrago-2-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-reports-phase-3-data-for-satralizumab-in-satrago-1-satrago-2-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RHHBY","BK4007","03165"],"gpt_icon":0},{"id":"2576068060","title":"Underwhelming Roche data helps Veridian’s position in TED, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2576068060","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576068060?lang=en_us&edition=fundamental","pubTime":"2025-10-18 01:55","pubTimestamp":1760723717,"startTime":"0","endTime":"0","summary":"Jefferies reiterated a Buy rating and $44 price target on Viridian Therapeutics (VRDN), noting the shares rose after Roche’s (RHHBY) mixed Phase 3 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/underwhelming-roche-data-helps-veridians-position-in-ted-says-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/underwhelming-roche-data-helps-veridians-position-in-ted-says-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VRDN","RHHBY","BK4139","BK4007","03165"],"gpt_icon":0},{"id":"2576700422","title":"Berenberg Bank Reaffirms Their Hold Rating on Roche Holding (RHHBY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2576700422","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576700422?lang=en_us&edition=fundamental","pubTime":"2025-10-17 13:15","pubTimestamp":1760678127,"startTime":"0","endTime":"0","summary":"Berenberg Bank analyst maintained a Hold rating on Roche Holding yesterday and set a price target of $45.00. The company’s shares closed yesterday ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/berenberg-bank-reaffirms-their-hold-rating-on-roche-holding-rhhby-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/berenberg-bank-reaffirms-their-hold-rating-on-roche-holding-rhhby-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RHHBY"],"gpt_icon":0},{"id":"2576776903","title":"Roche Sets Gene-Sequencing Record. It's a Challenge for Illumina. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2576776903","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576776903?lang=en_us&edition=fundamental","pubTime":"2025-10-17 05:18","pubTimestamp":1760649480,"startTime":"0","endTime":"0","summary":"This week, the Broad Institute gene-sequencing lab said it read infants' DNA genomes in less than four hours, cutting an hour off the previous Guinness World Record. The point for investors is that the scientists used a new sequencing technology from Roche Diagnostics, rather than the tools of market leader Illumina.Illumina systems dominate gene sequencing in research labs and the clinic, so Roche will need to show impressive speed, accuracy and economics for its new products to make a dent in Illumina's $4 billion in annual sales. Broad's speed record news coincides with a genomics conference this week, where the sequencing rivals are showing off their newest technologies.Broad researchers said they demonstrated the feasibility of same-day reports of clinically relevant gene variants to those caring for newborns in intensive care. That is getting close to the turnaround time for other clinical lab tests. Fast sequencing could also make a difference in treating infections.Illumina tol","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03165","BK4548","BK4534","BK4585","BK4121","BK4588","BK4535","ILMN","RHHBY","BK4007"],"gpt_icon":0},{"id":"2576254127","title":"Roche announces Direct-to-Patient program for Xofluza","url":"https://stock-news.laohu8.com/highlight/detail?id=2576254127","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576254127?lang=en_us&edition=fundamental","pubTime":"2025-10-16 23:50","pubTimestamp":1760629814,"startTime":"0","endTime":"0","summary":"Genentech, a member of the Roche (RHHBY) Group, announced the company’s first Direct-to-Patient program. “This program, which supports President Tr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-announces-direct-to-patient-program-for-xofluza-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-announces-direct-to-patient-program-for-xofluza-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","03165","RHHBY"],"gpt_icon":0},{"id":"2575856762","title":"Roche Holding AG Flat Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2575856762","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575856762?lang=en_us&edition=fundamental","pubTime":"2025-10-14 00:17","pubTimestamp":1760372220,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  were flat  at CHF290.10 Monday on what proved to be an overall mediocre trading session for the stock market, with the   holding steady at 12,484.80.This was the stock's second consecutive day of losses.Roche Holding AG closed CHF23.70 below its 52-week high of CHF313.80, which the company reached on March 12, 2025.Trading volume was 707,999, compared to the 50-day average trading volume of 1,045,097.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AG","RHHBY","03165","BK4210","BK4007"],"gpt_icon":0},{"id":"2575352404","title":"Roche Gets FDA Approval For Alzheimer's Disease Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2575352404","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575352404?lang=en_us&edition=fundamental","pubTime":"2025-10-13 21:27","pubTimestamp":1760362020,"startTime":"0","endTime":"0","summary":"The FDA approved a blood test developed by Roche and Eli Lilly to aid in the initial assessment for Alzheimer's disease.The test, called Elecsys pTau181, is intended for patients 55 and older presenting signs of cognitive decline and allows physicians to rule out Alzheimer's pathology.Roche said the test would help patients get answers earlier in their journey of cognitive decline and would expand the availability of Alzheimer's diagnosis tools to primary-care doctors.In a study of 312 patients, the test ruled out Alzheimer's pathology with a probability of 97.9% accuracy, Roche said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Roche Gets FDA Approval For Alzheimer's Disease Test","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03165","LU1069344957.HKD","SGXZ57979304.SGD","LU0256863811.USD","LU2237443382.USD","LU0823434583.USD","SG9999015986.USD","LU2491050071.SGD","LU1061106388.HKD","LU2468319806.SGD","BK4533","LU2360106947.USD","SG9999017495.SGD","LU1868836914.USD","LU1868836591.USD","LU1868837300.USD","LU2106854487.HKD","LU0096364046.USD","LU1064131342.USD","LU0708995401.HKD","LU0061475181.USD","LU2491050154.USD","LU0823434740.USD","SG9999013999.USD","LU0058720904.USD","IE00BK4W5M84.HKD","BK4534","LU0323591593.USD","LU2237443465.HKD","LU1868837136.USD","IE00BK4W5L77.USD","RHHBY","LU2108987350.USD","LU0432979614.USD","LU0256863902.USD","BK4581","LU0353189680.USD","LU2324357040.USD","LU0823416689.USD","LU2087625088.SGD","LU1988902786.USD","LU2461242641.AUD","LU1974910355.USD","LU0079474960.USD","LU1989771016.USD","LU2237443895.HKD","LU2417539215.USD","LU1093756168.USD","LU0234572021.USD"],"gpt_icon":1},{"id":"2575940567","title":"Roche to present 30 abstracts at ESMO, evERA study met co-primary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2575940567","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575940567?lang=en_us&edition=fundamental","pubTime":"2025-10-13 19:55","pubTimestamp":1760356512,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) announced that it will present more than 30 abstracts across more than 10 cancer types at the European Society for Medical Oncology, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-to-present-30-abstracts-at-esmo-evera-study-met-co-primary-endpoints-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-to-present-30-abstracts-at-esmo-evera-study-met-co-primary-endpoints-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["03165","RHHBY","BK4007"],"gpt_icon":0},{"id":"2574015995","title":"AstraZeneca's Enhertu Could Become Top Early Breast Cancer Therapy -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2574015995","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574015995?lang=en_us&edition=fundamental","pubTime":"2025-10-09 19:17","pubTimestamp":1760008620,"startTime":"0","endTime":"0","summary":"1102 GMT - AstraZeneca's multi-use cancer drug Enhertu is on course to become the new benchmark treatment for early-stage breast cancer, UBS analysts write in a note. Enhertu sales could peak at $1.5 billion after pivotal pre- and post-surgery trials, the analysts say. The medication showed significant benefits and a strong safety profile, suggesting it could displace Roche's Kadcyla as the top treatment for early breast cancer, the analysts add. It remains unclear how Enhertu's tolerability compares to Kadcyla's, and results show it is only effective in combination treatments, UBS says. Still, the analysts see Enhertu on a clear path toward cementing its prominent role across pre- and post-surgery care. Shares trade flat at 128.08 pounds. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4588","LU0320765992.SGD","LU2462157665.USD","AZN","LU2456880835.USD","RHHBY","LU0889565916.HKD","03165","LU0109394709.USD","LU2236285917.USD","LU2417539215.USD","LU1829250122.USD","BK4585","BK4007"],"gpt_icon":0},{"id":"2574978510","title":"Roche Holding AG Rises Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2574978510","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574978510?lang=en_us&edition=fundamental","pubTime":"2025-10-09 00:17","pubTimestamp":1759940220,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  advanced 1.0% to CHF291.30 Wednesday on what proved to be an overall positive trading session for the stock market, with the   rising 1.0% to 12,648.11.This was the stock's eighth consecutive day of gains.Roche Holding AG closed CHF22.50 below its 52-week high of CHF313.80, which the company reached on March 12, 2025.Trading volume was 1,169,583, compared to the 50-day average trading volume of 1,033,336.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","03165","BK4007","AG","BK4210"],"gpt_icon":0},{"id":"2572529429","title":"Roche's Genentech Gets FDA Approval for Lung Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2572529429","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572529429?lang=en_us&edition=fundamental","pubTime":"2025-10-03 06:48","pubTimestamp":1759445280,"startTime":"0","endTime":"0","summary":"Roche's Genentech received approval from the Food and Drug Administration for its drugs Tecentriq and Tecentriq Hybreza to be used in combination with lurbinectedin to treat lung cancer.It is the first and only approval of a combination therapy for the first-line maintenance treatment for adults with  extensive-stage small cell lung cancer, an aggressive disease with limited treatments, Genentech said Thursday.The approval is based on results from a Phase 3 study, which showed a combination of Tecentriq and lurbinectedin reduced the risk of disease progression or death by 46%, and reduced the risk of death by 27%, compared with Tecentriq alone.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Roche's Genentech Gets FDA Approval for Lung Cancer Treatment","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RHHBY","03165"],"gpt_icon":0},{"id":"2572252997","title":"FDA approves Genentech’s Tecentriq + Lurbinectedin in ES-SCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2572252997","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572252997?lang=en_us&edition=fundamental","pubTime":"2025-10-03 06:35","pubTimestamp":1759444508,"startTime":"0","endTime":"0","summary":"Genentech, a member of the Roche (RHHBY) Group, announced that the FDA has approved Tecentriq and Tecentriq Hybreza in combination with lurbinected...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-approves-genentechs-tecentriq-lurbinectedin-in-es-sclc-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-approves-genentechs-tecentriq-lurbinectedin-in-es-sclc-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BMG7P587.USD","BK4007","IE00BMG7P819.SGD","RHHBY","IE00BMG7P926.USD","BK4081","03165","IE00B29SXL02.USD","BK4588","LU1883839398.USD","LU2449327464.USD","BK4585","IE00BZ18W456.USD","IE00BMG7P694.USD","IE00BZ18W340.USD","IE00BMQBXF63.USD","IE00B29SXK94.USD","LU1880398554.USD","LU2637428348.USD","ES","LU1803068623.USD","LU1880398471.USD"],"gpt_icon":0},{"id":"2572582157","title":"Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2572582157","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572582157?lang=en_us&edition=fundamental","pubTime":"2025-10-01 17:05","pubTimestamp":1759309500,"startTime":"0","endTime":"0","summary":"Lithium Americas : The U.S. government said Tuesday it would take a 5% stake in both the Canadian company and its Nevada mining project. Shares jumped by roughly one-third in premarket trading.Nike : The retailer posted a surprise sales increase for last quarter, but raised its tariff-cost forecast to $1.5 billion this fiscal year. Shares climbed 3% ahead of the open.Arm : A U.S. court dismissed the chip designer's allegation that a Qualcomm  unit violated a licensing agreement. Arm shares fell around 2% before the bell.Novo Nordisk , AstraZeneca , Roche : Shares of European drugmakers rose after President Trump unveiled plans for a direct-to-consumer website where Americans could buy discounted medicines. The news lifted U.S. pharmaceutical stocks Tuesday.Occidental Petroleum : Warren Buffett's Berkshire Hathaway  is in talks to buy Occidental's petrochemical unit for around $10 billion. Occidental shares rose over 1% in premarket trading.AES : BlackRock-owned Global Infrastructure Pa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03165","ARM","LU1829250122.USD","CALM","LU1084165304.USD","SG9999015952.SGD","IE00BZ1G4Q59.USD","LU2098885051.SGD","BK4105","LU2168563687.JPY","LU1823568750.SGD","BK4201","AZN","LU2456880835.USD","LU0971096721.USD","LU0203345920.USD","IE00BSNM7G36.USD","LU0234572021.USD","LU1303367103.USD","IE00B1XK9C88.USD","RHHBY","LU0128525929.USD","LU1074936037.SGD","IE00BYQQ9H92.USD","LU0109394709.USD","SG9999015945.SGD","IE000M9KFDE8.USD","AES","BK4212","IE00BVYPNQ40.USD","LU0203347892.USD","LU0234570918.USD","LU0348723411.USD","LU0154236417.USD","AYI","LU0787776722.HKD","BK4568","IE0034235303.USD","NKE","LU0054578231.USD","LU2168564495.EUR","LAC","IE00BJLML261.HKD","LU1201861249.SGD","CAG","BK4612"],"gpt_icon":1},{"id":"2570470070","title":"U.S. Tariffs Pose Limited Risk to Big Swiss Pharma Groups -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2570470070","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570470070?lang=en_us&edition=fundamental","pubTime":"2025-09-26 16:05","pubTimestamp":1758873900,"startTime":"0","endTime":"0","summary":"0805 GMT - President Trump's drug tariffs will have a limited impact on big Swiss pharma players given their U.S. presence, Vontobel analysts write. While there is broad room for interpretation of Trump's announcement, Roche and Novartis are shielded by their U.S. footprints, while Sandoz should be unaffected since it focuses on exempted generic products, the analysts say. Galderma's exposure is less clear as it has a smaller U.S. presence. Tariffs will increase U.S. drug prices and supply concerns, but they shouldn't threaten the country's leading position in drug production, Vontobel says. Galderma shares fall 3.2%, with Roche and Novartis down 0.3% and 0.2%, respectively. Sandoz shares trade broadly flat. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","RHHBY","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","03165","LU0211331839.USD","BK4532","BK4585","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4578","LU0320765489.SGD","BK4007","IE00B4R5TH58.HKD","LU0208291251.USD","LU0070302665.USD","NVS","BK4588","IE0009355771.USD"],"gpt_icon":0},{"id":"2570077446","title":"European Pharmaceutical Stocks Fall On New Trump Tariffs -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2570077446","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570077446?lang=en_us&edition=fundamental","pubTime":"2025-09-26 15:38","pubTimestamp":1758872280,"startTime":"0","endTime":"0","summary":"0737 GMT - European pharmaceutical stocks fell in early trade after President Trump announced 100% tariffs on those companies that aren't building plants in the U.S. Swiss skincare company Galderma was the biggest faller, losing 3.55%, while Novo Nordisk shares are down 1.3%. AstraZeneca, Roche and Bayer shares were all down 0.2%. Tariffs are expected to start from Oct. 1.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03165","RHHBY","BK4599","IE00BZ1G4Q59.USD","BAYRY","BK4588","IE00BKVL7J92.USD","LU0320765992.SGD","LU1093756168.USD","AZN","LU0109394709.USD","LU2236285917.USD","LU1093756325.SGD","LU1829250122.USD","BK4532","BK4568","LU2456880835.USD","NVO","BK4585","LU0889565916.HKD","BK4007","LU0154236417.USD","LU2462157665.USD","LU2417539215.USD"],"gpt_icon":1},{"id":"2570249029","title":"Trump to Slap New Tariffs on Pharma, Big Trucks -- 2nd Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2570249029","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570249029?lang=en_us&edition=fundamental","pubTime":"2025-09-26 09:21","pubTimestamp":1758849660,"startTime":"0","endTime":"0","summary":"President Trump announced many new tariffs Thursday, including a large one on drugs from pharmaceutical companies that aren't building plants in the U.S.\"Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America,\" Trump posted on his social-media site, Truth Social, without providing details.Roughly nine out of 10 prescriptions in the U.S. are filled with generic drugs, which wouldn't be affected by a tariff on \"branded or patented\" products, as Trump outlined.This summer the Trump administration placed a 15% tariff on most pharmaceuticals coming from the European Union.Other tariffs Trump announced Thursday include ones on large trucks and home goods. All of them will begin Oct. 1, he said.Heavy trucks brought from outside the U.S. will be hit with a 25% tariff, Trump said.Kitchen cabinets, bathroom vanities and other similar products will get a 50% t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"243a0ccaa48d4fa4e3c6e75619262dec","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Trump to Slap New Tariffs on Pharma, Big Trucks -- 2nd Update","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","03165","RHHBY"],"gpt_icon":0},{"id":"2569774423","title":"Genentech presents new Ocrevus, fenebrutinib data at ECTRIMS congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2569774423","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569774423?lang=en_us&edition=fundamental","pubTime":"2025-09-24 17:15","pubTimestamp":1758705310,"startTime":"0","endTime":"0","summary":"Genentech, a member of Roche (RHHBY), presented new data for Ocrevus and the investigational Bruton’s tyrosine kinase inhibitor fenebrutinib at the...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genentech-presents-new-ocrevus-fenebrutinib-data-at-ectrims-congress-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genentech-presents-new-ocrevus-fenebrutinib-data-at-ectrims-congress-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["03165","RHHBY","BK4007"],"gpt_icon":0},{"id":"2569313477","title":"Oppenheimer reiterates Buy on Olema, sees evERA readthrough to persevERA","url":"https://stock-news.laohu8.com/highlight/detail?id=2569313477","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569313477?lang=en_us&edition=fundamental","pubTime":"2025-09-23 01:00","pubTimestamp":1758560413,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Matthew Biegler notes that Olema (OLMA) shares are up today, likely on news that Roche’s (RHHBY) evERA trial was a success. “No...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oppenheimer-reiterates-buy-on-olema-sees-evera-readthrough-to-persevera-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oppenheimer-reiterates-buy-on-olema-sees-evera-readthrough-to-persevera-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","BK4139","03165","BK4007","OPY","BK4505","RHHBY","OLMA"],"gpt_icon":0},{"id":"2569826507","title":"Roche to Launch Late-Stage Trial of Experimental Obesity Drug in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2569826507","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569826507?lang=en_us&edition=fundamental","pubTime":"2025-09-22 20:36","pubTimestamp":1758544560,"startTime":"0","endTime":"0","summary":"Roche plans to move one of its weight-loss treatment candidates to late-stage trials next year, as the Swiss pharmaceutical group aims to become a top-three player in the booming market.The group said Monday that the experimental drug, called CT-388, showed strong efficacy in early-stage studies and that mid-stage trials were under way. A late-stage, or phase 3, study is set to begin in the first half of 2026, it said.Roche's aim is to become a strong entrant in the weight-loss market before 2030 and eventually a top-three competitor in the field, the head of the group's pharmaceuticals business, Teresa Graham, said at a company event with investors in London.U.S.-based Eli Lilly and Denmark's Novo Nordisk currently dominate the market, with other companies such as Amgen and AstraZeneca trying to catch up. Pfizer on Monday agreed to buy weight-loss drug developer Metsera for up to $7.3 billion in a bid to get back into the burgeoning market.CT-388 is a medication injected weekly that, ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"c8c015636e69da2c01039595706c31dc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SSI","RHHBY","03165"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":82,"code":"91000000","status":"200"}]}}